Clearside Biomedical (CLSD) announced that presentations highlighting Clearside’s suprachoroidal delivery technology and data on its pipeline programs were delivered in medical meetings in Asia, Europe and the United States. Most prominently, Clearside’s progress was featured in multiple activities at the 17th Asia-Pacific Vitreo-Retina Society, APVRS, Congress that took place November 22-24, 2024 in Singapore. In addition, Clearside’s technology and recent ODYSSEY topline data results for CLS-AX in wet AMD were highlighted at the Ophthalmology Innovation Summit, OIS, event November 22-23, 2024 in San Diego, CA and will be presented at the upcoming FLORetina 12th International Congress on OCT and OCT Angiography in Florence, Italy being held December 5-8 2024.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLSD:
- Clearside Biomedical Reports Positive Q3 2024 Results
- Clearside Biomedical reports Q3 EPS (10c), consensus (12c)
- CLSD Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Clearside Biomedical’s partner signed new collaboration agreement with Santen
- Clearside Biomedical appoints Gibney as new Chair of board of directors